EMC Capital Management Buys New Shares in Jazz Pharmaceuticals PLC $JAZZ

EMC Capital Management purchased a new position in Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 3,237 shares of the specialty pharmaceutical company’s stock, valued at approximately $344,000. Jazz Pharmaceuticals comprises 0.2% of EMC Capital Management’s holdings, making the stock its 28th biggest holding.

A number of other institutional investors and hedge funds also recently modified their holdings of JAZZ. Philip James Wealth Mangement LLC raised its position in shares of Jazz Pharmaceuticals by 42.0% during the second quarter. Philip James Wealth Mangement LLC now owns 15,797 shares of the specialty pharmaceutical company’s stock worth $1,676,000 after purchasing an additional 4,675 shares during the period. State of Alaska Department of Revenue increased its stake in Jazz Pharmaceuticals by 75.1% in the 2nd quarter. State of Alaska Department of Revenue now owns 57,933 shares of the specialty pharmaceutical company’s stock worth $6,147,000 after purchasing an additional 24,850 shares in the last quarter. Inspire Investing LLC acquired a new stake in Jazz Pharmaceuticals during the 1st quarter worth about $689,000. Baird Financial Group Inc. purchased a new stake in Jazz Pharmaceuticals during the first quarter valued at about $539,000. Finally, Voya Investment Management LLC boosted its holdings in shares of Jazz Pharmaceuticals by 67.1% in the first quarter. Voya Investment Management LLC now owns 56,349 shares of the specialty pharmaceutical company’s stock worth $6,996,000 after buying an additional 22,628 shares during the period. Institutional investors and hedge funds own 89.14% of the company’s stock.

Jazz Pharmaceuticals Trading Up 6.1%

Jazz Pharmaceuticals stock opened at $180.52 on Wednesday. The company’s fifty day simple moving average is $135.92 and its 200-day simple moving average is $121.19. The company has a quick ratio of 1.37, a current ratio of 1.62 and a debt-to-equity ratio of 1.17. Jazz Pharmaceuticals PLC has a 12 month low of $95.49 and a 12 month high of $182.99. The stock has a market cap of $10.97 billion, a P/E ratio of -26.82, a P/E/G ratio of 8.49 and a beta of 0.29.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last announced its quarterly earnings data on Wednesday, November 5th. The specialty pharmaceutical company reported $8.13 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.87 by $2.26. Jazz Pharmaceuticals had a positive return on equity of 5.02% and a negative net margin of 9.91%.The business had revenue of $1.13 billion during the quarter, compared to analyst estimates of $1.11 billion. During the same period last year, the company earned $6.54 earnings per share. Jazz Pharmaceuticals’s quarterly revenue was up 6.7% compared to the same quarter last year. Jazz Pharmaceuticals has set its FY 2025 guidance at 7.650-8.450 EPS. As a group, sell-side analysts forecast that Jazz Pharmaceuticals PLC will post 16.96 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

JAZZ has been the topic of a number of recent analyst reports. JPMorgan Chase & Co. cut their price target on shares of Jazz Pharmaceuticals from $204.00 to $199.00 and set an “overweight” rating on the stock in a report on Monday, October 27th. The Goldman Sachs Group boosted their target price on shares of Jazz Pharmaceuticals from $162.00 to $185.00 and gave the company a “buy” rating in a research note on Friday, August 29th. Bank of America increased their target price on Jazz Pharmaceuticals from $230.00 to $247.00 and gave the company a “buy” rating in a report on Tuesday. Zacks Research upgraded Jazz Pharmaceuticals from a “strong sell” rating to a “hold” rating in a report on Friday, August 15th. Finally, Needham & Company LLC reissued a “buy” rating and issued a $202.00 price objective on shares of Jazz Pharmaceuticals in a research note on Thursday, August 28th. Fourteen research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Jazz Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus price target of $195.07.

Insider Activity

In related news, Director Bruce C. Cozadd sold 3,500 shares of the business’s stock in a transaction that occurred on Friday, October 3rd. The stock was sold at an average price of $140.00, for a total value of $490,000.00. Following the completion of the sale, the director owned 408,826 shares of the company’s stock, valued at approximately $57,235,640. The trade was a 0.85% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. In the last three months, insiders sold 11,500 shares of company stock worth $1,525,280. 4.30% of the stock is owned by insiders.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.